Peregrine Capital Management LLC Raises Holdings in Bruker Corporation $BRKR

Key Points

• Peregrine Capital massively increased its stake in Bruker, boosting holdings by 27,660.8% to own 138,804 shares (about $6.54M), representing roughly 0.09% of the company.
• Analysts hold a mixed view: MarketBeat's consensus is a Hold with a $49.38 average target, while several firms (including Barclays and Goldman) have recently cut price targets and ratings range from Strong Buy to Sell.
• Bruker missed quarterly EPS ($0.59 vs. $0.65 expected), set FY2026 guidance of 2.10–2.15 EPS, and its shares traded down roughly 8.7% to $36.22.

Peregrine Capital Management LLC increased its holdings in Bruker Corporation (NASDAQ:BRKR - Free Report) by 27,660.8% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 138,804 shares of the medical research company's stock after acquiring an additional 138,304 shares during the period. Peregrine Capital Management LLC owned approximately 0.09% of Bruker worth $6,539,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in BRKR. Sector Gamma AS boosted its position in shares of Bruker by 28.0% during the third quarter. Sector Gamma AS now owns 250,909 shares of the medical research company's stock worth $8,152,000 after buying an additional 54,939 shares during the period. Becker Capital Management Inc. boosted its position in shares of Bruker by 606.8% during the third quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company's stock worth $9,800,000 after buying an additional 258,545 shares during the period. DNB Asset Management AS boosted its position in shares of Bruker by 40.5% during the third quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company's stock worth $4,654,000 after buying an additional 41,289 shares during the period. Aquatic Capital Management LLC boosted its position in shares of Bruker by 120.3% during the third quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company's stock worth $11,358,000 after buying an additional 190,883 shares during the period. Finally, M&G PLC boosted its position in shares of Bruker by 233.0% during the third quarter. M&G PLC now owns 1,096,226 shares of the medical research company's stock worth $35,079,000 after buying an additional 766,992 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BRKR has been the subject of several research analyst reports. TD Cowen upgraded Bruker to a "hold" rating in a research report on Monday, April 13th. Barclays lowered their price target on Bruker from $50.00 to $45.00 and set an "overweight" rating for the company in a research report on Tuesday, April 14th. The Goldman Sachs Group lowered their price target on Bruker from $40.00 to $35.00 and set a "sell" rating for the company in a research report on Friday, February 13th. Jefferies Financial Group set a $50.00 price target on shares of Bruker in a research report on Thursday, February 12th. Finally, Guggenheim decreased their price target on shares of Bruker from $58.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $49.38.

Insider Transactions at Bruker

In related news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 27.20% of the company's stock.

Bruker Trading Down 8.7%

NASDAQ:BRKR opened at $36.22 on Friday. The firm has a market cap of $5.51 billion, a PE ratio of -241.47, a price-to-earnings-growth ratio of 2.38 and a beta of 1.20. The stock has a fifty day moving average price of $37.32 and a 200 day moving average price of $41.87. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $56.22. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.65 by ($0.06). The company had revenue of $977.20 million during the quarter, compared to analysts' expectations of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company's revenue for the quarter was down .2% on a year-over-year basis. During the same quarter last year, the business posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were issued a $0.05 dividend. The ex-dividend date was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. Bruker's dividend payout ratio (DPR) is -133.33%.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Corporation (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.